Newsroom

2010

• Feb 22, 2010
  CellCentric Licenses Novel Epigenetic Discovery Programme to Takeda Pharmaceutical Company, Ltd
• Feb 18, 2010
  Domainex Ltd Announces Investment From Takeda Research Investment, Inc
• Jan 26, 2010
  Envoy Therapeutics, Inc. today announced that it has entered into a multi-year research collaboration agreement with an affiliate of Merck & Co., Inc. to discover novel diabetes and obesity drug targets. For full details, please click here here.
• Jan 25, 2010
  CellCentric, the biotechnology company unlocking epigenetic control mechanisms, has an ongoing research relationship with Prof. Wolf Reik at the Babraham Institute, Cambridge. New work from his lab published today in Nature, highlights the substantial degree to which DNA demethylation occurs in early mammalian development and that AID is a critical component of the process. It builds upon Wolf Reik’s earlier work on the biochemistry of AID’s activities in cells. For full details, please click here here.

2009

• Nov 11, 2009
  Envoy Therapeutics, Inc., a newly formed drug discovery company, today announced that it has secured a loan from Takeda Research Investment (TRI) which Envoy may elect to convert to Envoy preferred stock should the company complete a second private equity financing. TRI will receive certain rights from Envoy related to a specific therapeutic field while scientists at the two companies craft a broad scientific research alliance. For full details, please click here.
• Oct 14, 2009
  Envoy Therapeutics, a new drug discovery company based in Jupiter FL, announces the successful closing of its first financing, an $8 million private placement of the company's Series A Preferred Stock. Led by 5AM Ventures, other investors participating in the financing included Takeda Research Investment and Roche Venture Fund. For full details, please click here.
• Jun 02, 2009
  CellCentric announces that the company is hosting a conference and celebration of Imprinting and Epigenetics, at the University of Cambridge on September 4-6th 2009. For full details, please click here.